ClinicalTrials.gg
Active, not recruitingNCT06051695EVEREST-2Updated Nov 16, 2026

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

A Phase 1/2 interventional study of A2B694 and A2B543 in Solid Tumor, Adult, Colorectal Cancer and NSCLC, sponsored by A2 Biotherapeutics Inc.. Active, not recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-16.

Primary conditionNeoplasms(registry's first term: Colorectal Neoplasms)Many cancersIs this wrong?The study is open to many cancers (its listed conditions name solid tumors in general), and its title does not single out Colorectal Neoplasms, so we do not take that as its main condition. It is compared within Neoplasms.

Sponsored by A2 Biotherapeutics Inc. · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 16, 2026Now Active, not recruitingGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
474
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to test autologous logic-gated Tmod™ CAR T-cell products in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), ovarian cancer (OVCA), mesothelioma (MESO), and other solid tumors that express mesothelin (MSLN) and have lost HLA-A*02 expression.

The main questions this study aims to answer are:

Phase 1: What is the recommended dose that is safe for patients

Phase 2: Does the recommended dose kill solid tumor cells and protect the patient's healthy cells

Participants will be required to perform study procedures and assessments, and will also receive the following study treatments:

Enrollment and Apheresis in BASECAMP-1 (NCT04981119)

Preconditioning Lymphodepletion (PCLD) Regimen

Tmod CAR T cells at the assigned dose

Read the detailed description

This is a seamless phase 1/2, multi-center, open-label study that enrolls adults with recurrent unresectable, locally advanced, or metastatic (considered non-curative) CRC, NSCLC, PANC, OVCA, MESO or other solid tumors with MSLN expression. Subjects must be germline HLA-A*02 heterozygous, with tumors that express MSLN and have lost HLA-A*02 expression. This study has two arms: Arm 1 is a study of A2B694 and Arm 2 is a study of A2B543.

The purpose of Phase 1 of this study is to determine the safety and the optimal dose of the Tmod products (after PCLD) in participants with solid tumor disease. The purpose of Phase 2 of this study is to determine the further safety and efficacy (how well it treats the solid tumor disease) of the Tmod products.

The treatment available for these cancers and other solid tumors can be toxic, debilitating, and fatal. In the recurrent unresectable, locally advanced, or metastatic setting, the intent of standard of care treatment is typically palliative rather than curative, and has not changed significantly in several decades. A2 Bio hypothesizes that Tmod CAR T-cell therapy will enable the killing of tumor target cells (those cells that express MSLN and have loss of heterozygosity [LOH] for HLA-A*02 protein). Additionally, normal healthy cells that maintain HLA-A*02 expression and co-express MSLN (eg, lung tissue) will not be targeted due to the blocker portion of the Tmod CAR T cell that acts as a self-regulated safety switch that protects normal tissue from damage. A2 Bio believes this will provide a therapeutic safety window compared to previous solid tumor targeting therapies. This hypothesis will be explored in the study.

Participants for this study must enroll and have their T cells collected (apheresis) in the pre-screening BASECAMP-1 study (NCT04981119). T cells are collected, processed and stored for each participant. Upon disease progression the participant may screen for this study (EVEREST-2) and the participant's T cells are manufactured and then infused following PCLD regimen. There is no time requirement between the studies, and patients may go directly from BASECAMP-1 to EVEREST-2 based on their own disease course.

02

Conditions studied

  • Solid Tumor, Adult
  • Colorectal Cancer
  • NSCLC
  • Non Small Cell Lung Cancer
  • NSCLC, Recurrent
  • Non-Small Cell Squamous Lung Cancer
  • Pancreas Cancer
  • Pancreatic Neoplasm
  • Colorectal Adenocarcinoma
  • CRC
  • Colon Cancer
  • Rectal Cancer
  • Cancer
  • Ovarian Cancer
  • Ovarian Neoplasms
  • Mesothelioma
  • Mesothelioma, Malignant
  • Ovary Cancer
  • Lung Cancer
  • MESOM

Keywords

  • CAR T Cell
  • Solid Tumors
  • Autologous
  • T Cell
  • Mesothelin
  • MSLN
  • HLA-A2
  • Solid Tumors expressing MSLN
  • Pancreatic
  • Cell Therapy
  • Gene Therapy
  • blocker
  • Cancer
  • PANC
  • CRC
  • Colorectal Cancer
  • Lung Cancer
  • NSCLC
  • OVCA
  • MESOM
  • Ovarian Cancer
  • Mesothelioma
  • Logic-gate
03

In context

Neoplasms Many cancers

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 474 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

A2 Biotherapeutics Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.

Compared within Neoplasms: the study is open to many cancers; the registry's first condition term is Colorectal Neoplasms. Counted across the registry records on this site, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

Key Inclusion Criteria:

  1. Appropriately enrolled in the BASECAMP-1 A2 Biotherapeutics, Inc. study, with tissue demonstrating LOH of HLA-A*02 by NGS (whenever possible from the primary site), successful apheresis and PBMC processing, and with sufficient stored cells available for Tmod CAR T-cell therapy
  2. confirmed recurrent unresectable, locally advanced, or CRC, NSCLC, PANC, OVCA, MESO, or other solid tumors with MSLN expression. is required with lesions of ≥1.0 cm by CT.
  3. Received previous required therapy for the appropriate solid tumor disease as described in the protocol
  4. Has adequate organ function as described in the protocol
  5. performance status of 0 to 1
  6. of ≥3 months
  7. Willing to comply with study schedule of assessments including long term safety follow up

Key Exclusion Criteria:

  1. Has disease that is suitable for local therapy or able to receive standard of care therapy that is therapeutic and not palliative
  2. Prior stem cell transplant
  3. Prior solid organ transplant
  4. MESO with pleural involvement extending into the peritoneum
  5. Cancer therapy within 3 weeks or 3 half lives of infusion
  6. Radiotherapy within 28 days of infusion
  7. Unstable angina, arrhythmia, myocardial infarction, or any other significant cardiac disease within the last 6 months
  8. Any new symptomatic pulmonary embolism (PE) or a deep vein thrombosis (DVT) within 3 months of enrollment. Therapeutic dosing of anticoagulants is allowed for history of PE or DVT if greater than 3 months from time of enrollment, and adequately treated
  9. History of interstitial lung disease including drug-induced interstitial lung disease and radiation pneumonitis that requires treatment with prolonged or other immune suppressive agents within 1 year
  10. Requires supplemental home oxygen
  11. Females of who are pregnant or breastfeeding
  12. Subjects, both male and female, of childbearing potential who are not willing to practice from the time of consent through 6 months post infusion
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
474 participants (estimated)

Study arms

  • Experimental
    Arm 1: A2B694

    Patients receive preconditioning lymphodepletion (PCLD) regimen followed by a single dose of A2B694 intravenously on day 0

    Biological: A2B694 · Diagnostic Test: xT CDx with HLA-LOH Assay

  • Experimental
    Arm 2: A2B543

    Patients receive preconditioning lymphodepletion (PCLD) regimen followed by a single dose of A2B543 intravenously on day 0

    Biological: A2B543 · Diagnostic Test: xT CDx with HLA-LOH Assay

Interventions

  • BiologicalA2B694

    Autologous logic-gated Tmod CAR T cells

    Also known as: Tmod CAR T-cell Therapy

  • BiologicalA2B543

    Autologous logic-gated Tmod CAR T cells

    Also known as: Tmod CAR T-cell Therapy

  • Diagnostic testxT CDx with HLA-LOH Assay

    An investigational next generation sequencing (NGS) in vitro diagnostic (IVD) medical device

06

What researchers measure

Primary outcomes

  1. Phase 1: Rate of adverse events and dose limiting toxicities (DLTs) by dose level

    Adverse Events and toxicity will be evaluated according to the Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events version (CTCAE) 5.0 (or current version). Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) events will be graded according to the criteria described in the current protocol.

    Time frame: From the time of Informed consent until 24 months (2 years) post infusion

  2. Phase 1: Recommended Phase 2 Dose (RP2D)

    The RP2D will be identified utilizing a BOIN study design in addition to considering safety and biomarker analysis.

    Time frame: 21 days post infusion

  3. Phase 2: The Overall Response Rate (ORR) for patients

    The ORR will be evaluated per RECIST v1.1 and assessed by independent central review.

    Time frame: 24 months post infusion

Secondary outcomes

  1. Persistence of Tmod product

    Number of Tmod CAR T cells present as assessed by polymerase chain reaction (PCR) (or similar method) on participant blood samples

    Time frame: up to 24 months post infusion

  2. Cytokine analysis

    Cytokine levels such as interferon-gamma (IFN-γ) and interleukin-6 (IL-6) assessed by cytokine analysis on participant blood samples

    Time frame: up to 24 months post infusion

07

Study locations

12 sites
08

References and documents

Publications

  • Hamburger AE, DiAndreth B, Cui J, Daris ME, Munguia ML, Deshmukh K, Mock JY, Asuelime GE, Lim ED, Kreke MR, Tokatlian T, Kamb A. Engineered T cells directed at tumors with defined allelic loss. Mol Immunol. 2020 Dec;128:298-310. doi: 10.1016/j.molimm.2020.09.012. Epub 2020 Oct 1. PubMed 33012527 ↗
  • Hwang MS, Mog BJ, Douglass J, Pearlman AH, Hsiue EH, Paul S, DiNapoli SR, Konig MF, Pardoll DM, Gabelli SB, Bettegowda C, Papadopoulos N, Vogelstein B, Zhou S, Kinzler KW. Targeting loss of heterozygosity for cancer-specific immunotherapy. Proc Natl Acad Sci U S A. 2021 Mar 23;118(12):e2022410118. doi: 10.1073/pnas.2022410118. PubMed 33731480 ↗
  • Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, Mc Henry KT, Pinchback RM, Ligon AH, Cho YJ, Haery L, Greulich H, Reich M, Winckler W, Lawrence MS, Weir BA, Tanaka KE, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Gao Q, Yecies D, Signoretti S, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Tabernero J, Baselga J, Tsao MS, Demichelis F, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Golub TR, Lander ES, Getz G, Sellers WR, Meyerson M. The landscape of somatic copy-number alteration across human cancers. Nature. 2010 Feb 18;463(7283):899-905. doi: 10.1038/nature08822. PubMed 20164920 ↗
  • Tokatlian T, Asuelime GE, Mock JY, DiAndreth B, Sharma S, Toledo Warshaviak D, Daris ME, Bolanos K, Luna BL, Naradikian MS, Deshmukh K, Hamburger AE, Kamb A. Mesothelin-specific CAR-T cell therapy that incorporates an HLA-gated safety mechanism selectively kills tumor cells. J Immunother Cancer. 2022 Jan;10(1):e003826. doi: 10.1136/jitc-2021-003826. PubMed 35091455 ↗

Individual participant data

Plan to share: Yes — Study data will be shared within 1 year of study completion.

Supporting information: Clinical study report

Time frame: Data will be available within 1 year of the completion of the study, the length of time of availability is to be determined.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jun 2028, 50 months after the start.

Of 197 industry-sponsored phase 1/2 interventional studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 88. This study's planned 50 months is below that.

Counting every sponsor, half of 299 studies reached it within 61 months; a quarter within 40 and three quarters within 89.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2023
First posted
Sep 25, 2023
StartActual
Apr 3, 2024
Primary completionEst.
Jun 2028
CompletionEst.
Jun 2029
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Recruiting→Active, not recruiting
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06051695
Lead sponsor
A2 Biotherapeutics Inc.
Collaborators
Tempus AI
Responsible party
Sponsor
First posted
Sep 25, 2023
Start date
Apr 3, 2024
Primary completion
Jun 2028 (estimated)
Completion
Jun 2029 (estimated)
Last update
Nov 16, 2026

Study contacts

John Welch, MD, PhD
study director · A2 Biotherapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion